Tebentafusp (IMCgp100; IImmunocore) demonstrated superior overall survival (OS) compared to the investigator’s choice in a phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma (mUM), according to a press release.

In the intent-to-treat population, OS Hazard Ratio (HR) favored tebentafusp over investigator’s choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine). The…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

Journal Scan

  1. Nov 05, 2020

Neighborhood-poverty linked with poor outcomes in pediatric hematopoietic cell transplantation

Social determinants of health, including poverty, contribute significantly to health outcomes in the United States, yet their impact on pediatric hematopoietic cell transplantation (HCT) outcomes is poorly understood. We aimed to identify the association between…